{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:13:46Z","timestamp":1785406426676,"version":"3.56.0"},"reference-count":18,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Anticoagulation therapy is essential to manage thromboembolic conditions such as atrial fibrillation and venous thromboembolism. While effective, it carries significant bleeding risks, with annual rates ranging from 10\u201317% for all events and 2\u20135% for major bleeding. Anemia is an independent risk factor for anticoagulation-associated bleeding; however, guidelines lack recommendations for anemia screening and management before initiation.<\/jats:p>\n                  <jats:p>In a retrospective analysis of 170 anticoagulated patients (mean age 63.7; 96 males, 74 females), 51.2% had baseline anemia. Anemia severity was significantly associated with bleeding events (\u03c7\u00b2=15.7, p=0.003). Multivariate analysis confirmed that moderate (aOR=0.26, 95% CI:0.08\u20130.82, p=0.021) and no anemia (aOR=0.42, 95% CI:0.22\u20130.82, p=0.011) were associated with lower bleeding risk than mild anemia, while severe anemia remained uninterpretable due to small sample size. Patients aged \u226565 had higher bleeding risk (OR=2.8, 95% CI:1.5\u20135.1, p&lt;0.01), though this did not reach significance in multivariate analysis (aOR=1.80, 95% CI:0.95\u20133.41, p=0.073). Multivariate analysis confirmed higher bleeding risks for warfarin (aOR=4.13, 95% CI:1.91\u20138.96, p&lt;0.001) and rivaroxaban (aOR=3.67, 95% CI:1.69\u20137.97, p=0.001) compared to apixaban.<\/jats:p>\n                  <jats:p>Our study found an association between anemia and bleeding events, though severe anemia did not correlate with bleeding, possibly due to small sample size. Direct oral anticoagulants like apixaban and rivaroxaban present lower bleeding risks than warfarin. Given anemia\u2019s role in bleeding risk, we recommend routine screening before initiating anticoagulation to improve patient safety. Early assessment may help reduce bleeding complications, particularly in high-risk populations. Future studies should focus on multi-center trials to validate these findings and explore anemia subtypes.<\/jats:p>","DOI":"10.46989\/001c.138102","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:12:26Z","timestamp":1748337146000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Anemia Management on Bleeding Outcomes in Anticoagulated Patients: A Retrospective Cohort Analysis"],"prefix":"10.46989","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3227-368X","authenticated-orcid":true,"given":"Shea-Lee","family":"Godin","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02der9h97","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, University of Connecticut Health, Farmington, Connecticut, USA"},{"name":"Department of Medicine, St. Francis Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hanna","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02der9h97","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Medicine, University of Connecticut Health, Farmington, Connecticut, USA"},{"name":"Department of Medicine, St. Francis Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Naut","sequence":"additional","affiliation":[{"name":"Department of Medicine, St. Francis Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhanshu","family":"Mulay","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, St. Francis Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.amjmed.2015.10.001","article-title":"Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin","volume":"129","author":"K. Senoo","year":"2016","journal-title":"The American journal of medicine"},{"issue":"5","key":"ref2","doi-asserted-by":"publisher","first-page":"574.e13","DOI":"10.1016\/j.amjmed.2017.11.046","article-title":"The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants","volume":"131","author":"G. Y. H. Lip","year":"2018","journal-title":"The American journal of medicine"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.thromres.2021.05.007","article-title":"The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE","volume":"203","author":"S. Goto","year":"2021","journal-title":"Thrombosis research"},{"issue":"5","key":"ref4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/jth.12874","article-title":"Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial","volume":"13","author":"B. D. Westenbrink","year":"2015","journal-title":"Journal of thrombosis and haemostasis: JTH"},{"issue":"12","key":"ref5","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"N. van Es","year":"2014","journal-title":"Blood"},{"issue":"4","key":"ref6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/jcpt.13130","article-title":"Restarting of anticoagulation in patients with atrial fibrillation after major bleeding: A meta-analysis","volume":"45","author":"Y. Zhou","year":"2020","journal-title":"Journal of clinical pharmacy and therapeutics"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review","volume":"40","author":"S. Ballestri","year":"2023","journal-title":"Advances in therapy"},{"issue":"4","key":"ref8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jth.14398","article-title":"Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis","volume":"17","author":"M. A. T. Elsebaie","year":"2019","journal-title":"Journal of thrombosis and haemostasis : JTH"},{"issue":"5","key":"ref9","doi-asserted-by":"publisher","first-page":"104718","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104718","article-title":"Racial Disparity in the Prescription of Anticoagulants and Risk of Stroke and Bleeding in Atrial Fibrillation Patients","volume":"29","author":"Y. G. Tedla","year":"2020","journal-title":"Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1160\/TH08-11-0730","article-title":"Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients","volume":"102","author":"G. Palareti","year":"2009","journal-title":"Thrombosis and haemostasis"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"P. M. Kuijer","year":"1999","journal-title":"Archives of internal medicine"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"N. Ru\u00edz-Gim\u00e9nez","year":"2008","journal-title":"Thrombosis and haemostasis"},{"issue":"3","key":"ref13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11239-018-1610-9","article-title":"Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism","volume":"45","author":"A. Kuperman","year":"2018","journal-title":"Journal of thrombosis and thrombolysis"},{"issue":"3","key":"ref14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-w","article-title":"Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention","volume":"95","author":"C. S. Landefeld","year":"1993","journal-title":"The American journal of medicine"},{"issue":"2","key":"ref15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/s0002-9343(89)80689-8","article-title":"Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy","volume":"87","author":"C. S. Landefeld","year":"1989","journal-title":"The American journal of medicine"},{"issue":"11","key":"ref16","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1111\/j.1538-7836.2010.03904.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"S. Schulman","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100994","DOI":"10.1016\/j.ijcha.2022.100994","article-title":"Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis","volume":"40","author":"N. Tanaka","year":"2022","journal-title":"International journal of cardiology. Heart & vasculature"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1042763","DOI":"10.3389\/fcvm.2022.1042763","article-title":"HAS-BLED vs. ORBIT scores in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis","volume":"9","author":"X. Liu","year":"2023","journal-title":"Frontiers in cardiovascular medicine"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/138102-impact-of-anemia-management-on-bleeding-outcomes-in-anticoagulated-patients-a-retrospective-cohort-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T13:08:28Z","timestamp":1750424908000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/138102-impact-of-anemia-management-on-bleeding-outcomes-in-anticoagulated-patients-a-retrospective-cohort-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.138102","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}